-
公开(公告)号：US20220348647A1
公开(公告)日：2022-11-03
申请号：US17853218
申请日：2022-06-29
Applicant: Janssen Biotech, Inc.
Inventor： Ken Boakye , Alfred Del Vecchio , John Kehoe , Eilyn Lacy , Lynne Murray , Mary Ryan , Sandra Santulli-Marotto , John Wheeler , Brian Whitaker , Alexey Teplyakov
IPC: C07K16/24
Abstract: The present invention relates to antibodies specifically binding CCL17, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.
-
公开(公告)号：US11078263B2
公开(公告)日：2021-08-03
申请号：US16111360
申请日：2018-08-24
Applicant: Janssen Biotech, Inc.
Inventor： Mark Chiu , Brian Whitaker , Di Zhang
IPC: C07K14/435 , C07K14/47 , C07K14/78 , C07K16/18 , C07K19/00 , A61K38/17 , A61K38/39 , A61K39/395 , C07K16/24 , A61P35/00 , C07K16/28 , C12N15/70
Abstract: FN3 domains that specifically bind FcγRII, their conjugates and antibody fusions, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making and using them.
-
公开(公告)号：US09944697B2
公开(公告)日：2018-04-17
申请号：US14534525
申请日：2014-11-06
Applicant: Janssen Biotech, Inc.
Inventor： Ken Boakye , Alfred Del Vecchio , John Kehoe , Eilyn Lacy , Lynne Murray , Mary Ryan , Sandra Santulli-Marotto , John Wheeler , Brian Whitaker , Alexey Teplyakov
CPC classification number: C07K16/24 , A61K39/00 , A61K2039/55522 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92
Abstract: The present invention relates to antibodies specifically binding CCL17, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.
-
4.发明申请公开(公告)号：US20150210756A1
公开(公告)日：2015-07-30
申请号：US14565069
申请日：2014-12-09
Applicant: New York University , Janssen Biotech, Inc.
Inventor： Victor J. Torres , Randall J. Brezski , Anthony Lynch , William Strohl , Brian Whitaker , Mark Chiu , Peter T. Buckley , Keri Dorn , Michelle Kinder
IPC: C07K16/12 , G01N33/569
CPC classification number: C07K16/1271 , C07K14/78 , C07K2317/30 , C07K2317/31 , C07K2317/51 , C07K2317/515 , C07K2318/00 , C07K2319/70 , G01N33/56938 , G01N2469/10
Abstract: The present application generally relates to multi-specific molecules that bind to multiple bacterial virulence factors, methods for producing these binding molecules, and the use of these binding molecules to treat bacterial infections. In particular, the binding molecules comprise at least two binding domains, preferably an antibody or antibody fragment and an alternative scaffold. The first binding domain is capable of binding to a glycosylated staphylococcal surface protein, preferably an SDR-containing protein. The second binding domain is capable of binding to a staphylococcal leukotoxin, preferably LukAB, LukD or LukE. These multi-specific binding compounds have killing activity against staphylococci and, thus, can be used in the treatment and/or amelioration of a Staphylococcus infection, including methicillin-resistant Staphylococcus aureus.
Abstract translation: 本申请通常涉及结合多种细菌毒力因子的多特异性分子，用于产生这些结合分子的方法，以及这些结合分子用于治疗细菌感染的用途。 特别地，结合分子包含至少两个结合结构域，优选抗体或抗体片段和替代性支架。 第一结合结构域能够结合糖基化的葡萄球菌表面蛋白，优选含有SDR的蛋白质。 第二结合结构域能够结合葡萄球菌白血病，优选LukAB，LukD或LukE。 这些多特异性结合化合物对葡萄球菌具有杀伤活性，因此可用于治疗和/或改善葡萄球菌感染，包括耐甲氧西林金黄色葡萄球菌。
-
Patent Agency Ranking
公开(公告)号：US20150125458A1
公开(公告)日：2015-05-07
申请号：US14534525
申请日：2014-11-06
Applicant: Janssen Biotech, Inc.
Inventor： Ken Boakye , Alfred Del Vecchio , John Kehoe , Eilyn Lacy , Lynne Murray , Mary Ryan , Sandra Santulli-Marotto , John Wheeler , Brian Whitaker , Alexey Teplyakov
IPC: C07K16/24
CPC classification number: C07K16/24 , A61K39/00 , A61K2039/55522 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92
Abstract: The present invention relates to antibodies specifically binding CCL17, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.
Abstract translation: 本发明涉及特异性结合CCL17的抗体，编码抗体或片段的多核苷酸，以及制备和使用上述物质的方法。
-
6.发明申请公开(公告)号：US20190062420A1
公开(公告)日：2019-02-28
申请号：US16111360
申请日：2018-08-24
Applicant: Janssen Biotech, Inc.
Inventor： Mark Chiu , Brian Whitaker , Di Zhang
Abstract: FN3 domains that specifically bind FcγRII, their conjugates and antibody fusions, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making and using them.
-
公开(公告)号：US11414484B2
公开(公告)日：2022-08-16
申请号：US17060362
申请日：2020-10-01
Applicant: Janssen Biotech, Inc.
Inventor： Ken Boakye , Alfred Del Vecchio , John Kehoe , Eilyn Lacy , Lynne Murray , Mary Ryan , Sandra Santulli-Marotto , John Wheeler , Brian Whitaker , Alexey Teplyakov
Abstract: The present invention relates to antibodies specifically binding CCL17, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.
-
公开(公告)号：US10087243B2
公开(公告)日：2018-10-02
申请号：US15584235
申请日：2017-05-02
Applicant: New York University , Janssen Biotech, Inc.
Inventor： Victor J. Torres , Randall J. Brezski , Anthony Lynch , William Strohl , Brian Whitaker , Mark Chiu , Peter T. Buckley , Keri Dorn , Michelle Kinder
Abstract: The present application generally relates to multi-specific molecules that bind to multiple bacterial virulence factors, methods for producing these binding molecules, and the use of these binding molecules to treat bacterial infections. In particular, the binding molecules comprise at least two binding domains, preferably an antibody or antibody fragment and an alternative scaffold. The first binding domain is capable of binding to a glycosylated staphylococcal surface protein, preferably an SDR-containing protein. The second binding domain is capable of binding to a staphylococcal leukotoxin, preferably LukAB, LukD or LukE. These multi-specific binding compounds have killing activity against staphylococci and, thus, can be used in the treatment and/or amelioration of a Staphylococcus infection, including methicillin-resistant Staphylococcus aureus.
-
公开(公告)号：US09644023B2
公开(公告)日：2017-05-09
申请号：US14565069
申请日：2014-12-09
Applicant: New York University , Janssen Biotech, Inc.
Inventor： Victor J. Torres , Randall J. Brezski , Anthony Lynch , William Strohl , Brian Whitaker , Mark Chiu , Peter T. Buckley , Keri Dorn , Michelle Kinder
IPC: C07K19/00 , C07K16/12 , G01N33/569
CPC classification number: C07K16/1271 , C07K14/78 , C07K2317/30 , C07K2317/31 , C07K2317/51 , C07K2317/515 , C07K2318/00 , C07K2319/70 , G01N33/56938 , G01N2469/10
Abstract: The present application generally relates to multi-specific molecules that bind to multiple bacterial virulence factors, methods for producing these binding molecules, and the use of these binding molecules to treat bacterial infections. In particular, the binding molecules comprise at least two binding domains, preferably an antibody or antibody fragment and an alternative scaffold. The first binding domain is capable of binding to a glycosylated staphylococcal surface protein, preferably an SDR-containing protein. The second binding domain is capable of binding to a staphylococcal leukotoxin, preferably LukAB, LukD or LukE. These multi-specific binding compounds have killing activity against staphylococci and, thus, can be used in the treatment and/or amelioration of a Staphylococcus infection, including methicillin-resistant Staphylococcus aureus.
-
-
-
-
-
-
-
-
Search Results
9
records
(took 0.023 seconds)
